Efficacy of chemotherapy plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: A meta-analysis and up-date

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 1, 2015, Pages 1434-1445

  Zhang, Guoliang ^a   Zhou, Xile ^a   Lin, Caizhao ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Bevacizumab; Chemotherapy; Meta analysis; Metastatic colorectal cancer

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ARTICLE; BIBLIOGRAPHIC DATABASE; BLEEDING; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DATA PROCESSING; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEVER; HUMAN; LEUKOPENIA; META ANALYSIS; METASTATIC COLORECTAL CANCER; OVERALL RESPONSE RATE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 84923052670     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Cooper K, Squires H, Carroll C, Papaioannou D, Booth A, Logan R, Maguire C, Hind D and Tappenden P. Chemoprevention of colorectal cancer: systematic review and economic evaluation. Heath Technol Assess 2010; 14: 1-206.
2. Siegel R, Ma J, Zou Z and Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29.
3. Siegel R, DeSantis C and Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin 2014; 64: 104-117.
4. Hawk ET and Levin B. Colorectal cancer prevention. J Clin Oncol 2005; 23: 378-391.
5. Mills S and Stamos MJ. Metastatic Colorectal Cancer. Complexities in Colorectal Surgery. Springer; 2014. pp: 91-104.
6. Kanas GP, Taylor A, Primrose JN, Langeberg WJ, Kelsh MA, Mowat FS, Alexander DD, Choti MA and Poston G. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol 2012; 4: 283.
7. Petrelli N, Douglass H, Herrera L, Russell D, Stablein D, Bruckner H, Mayer R, Schinella R, Green M and Muggia F. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 1989; 7: 1419-1426.
8. Douillard J, Cunningham D, Roth A, Navarro M, James R, Karasek P, Jandik P, Iveson T, Carmichael J and Alakl M. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047.
9. de Gramont Ad, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A and Freyer G. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
10. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC and Alberts SR. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
11. Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O’Neill V and Rugo HS. RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2011; 29: 4286-93.
12. Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL, Wong L, Fehrenbacher L, Abubakr Y and Saif MW. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008; 26: 3523-3529.
13. Ducreux M, Adenis A, Pignon JP, François E, Chauffert B, Ichanté J, Boucher E, Ychou M, Pierga JY and Montoto-Grillot C. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study). Eur J Cancer 2013; 49: 1236-1245.
14. Tol J, Koopman M, Rodenburg CJ, Cats A, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, Mol L, Antonini NF, Punt CJ. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol 2008; 19: 734-8.
15. Zhang H, Xu L and An G. Evaluation of bevadzumab combined with FOLFIRI as first-line treatment for patients with metastatic colorectal cancer. Cancer Res Pre Treat 2012; 39: 1001-1004.
16. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B and Novotny WF. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23: 3697-3705.
17. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang T-S and Rivera F. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
18. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S and Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patientswith metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65.
19. Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, Jonker D, Osborne S, Andre N and Waterkamp D. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 2013; 14: 1077-1085.
20. Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, Van Hazel GA, Robinson B, Broad A, Ganju V and Ackland SP. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 2010; 28: 3191-3198.
21. Guan ZZ, Xu JM, Luo RC, Feng FY, Wang LW, Shen L, Yu SY, Ba Y, Liang J and Wang D. Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. Chin JCancer 2011; 30: 682-689.
22. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S and Holmgren E. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
23. Stathopoulos GP, Batziou C, Trafalis D, Koutantos J, Batzios S, Stathopoulos J, Legakis J, Armakolas A. Treatment of colorectal cancer with and without bevacizumab: a phase III study. Oncol 2010; 78: 376-381.
24. Van Cutsem E and Oliveira J. Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20: iv61-iv63.
25. Yoo PS, Lopez-Soler RI, Longo WE and Cha CH. Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab. Clin Colorectal Cancer 2006; 6: 202-207.
26. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK and Pirotta N. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343: 905-914.
27. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M and Ganem G. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.
28. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D’Haens G, Pintér T, Lim R and Bodoky G. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.
29. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S and Radinsky R. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634.
30. Whyte S, Pandor A and Stevenson M. Bevacizumab for metastatic colorectal cancer. Pharmacoeconomics 2012; 30: 1119-1132.
31. Dai F, Shu L, Bian Y, Wang Z, Yang Z, Chu W and Gao S. Safety of bevacizumab in treating metastatic colorectal cancer: a systematic review and meta-analysis of all randomized clinical trials. Clin Drug Inves 2013; 33: 779-788.
32. Cao Y, Tan A, Gao F, Liu L, Liao C and Mo Z. A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int J Colorectal Dis 2009; 24: 677-685.
33. Macedo LT, da Costa Lima AB and Sasse AD. Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups. BMC Cancer 2012; 12: 89.
34. Wang M, Zheng X, Ruan X, Ye B, Cai L, Lin F, Tu J, Jiang F and Li S. Efficacy and safety of first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a meta-analysis. Chin Med J 2014; 127: 538-546.
35. Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF and Kabbinavar F. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23: 3502-3508.
36. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, Mazier M, Canon J, Georgoulias V, Peeters M, Bridgewater J, Cunningham D. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009; 20: 1842-1847.
37. Giantonio BJ, Catalano PJ, Meropol NJ, O’Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA and Benson AB. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544.
38. Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O and Borg C. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet oncol 2013; 14: 29-37.
39. Arnold D, Andre T, Bennouna J, Sastre J, Osterlund PJ, Greil R, Van Cutsem E, Von Moos R, Reyes-Rivera I and Bendahmane B. Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: results of a randomized phase III intergroup study (TML study). J Clin Oncol (Meeting Abstracts) 2012; 30: CRA3503.